Growing need for biopharmaceutical medicines has led to surge in demand to conduct plasmapheresis. In addition, surge in demand to conduct extracorporeal therapy is further expected to impact growth of the global plasmapheresis market positively. This Fact.MR report analyzes the expansion of global plasmapheresis market till date, and provides key insights on the growth of the market during the forecast period, 2017-2026.
A treatment method which developed over a period of two decades and involves the removal and replacement of patient’s circulating plasma is aimed to remove disease-linked molecules and hence interrupt disease progression. Plasmapherisis has been applied in the treatment of lupus nephritis in order to eliminate circulating immune complexes and pathogenic antibodies. Accordingly, patients with overwhelming disease in whom standard therapy does not work may use plasmapheresis treatment. As such, the case of thrombotic thrombocytopenic purpura (TTP) has surged in those with SLE. Thus, priority on upgrading healthcare infrastructure coupled with growing awareness on treating TTP and autoimmune diseases has been witnessed.
Get Free Sample Report Here:
https://www.factmr.com/connectus/sample?flag=S&rep_id=351
The global plasmapheresis market is likely to grow at a steady CAGR of over 7% during the forecast period 2017-2026, and reach a valuation of over US$ 1.5 Bn by the end of 2026. The market is likely to be impacted by a range of macro-economic and micro-economic factors. Increasing emphasis on upgrading healthcare infrastructure, combined with higher awareness on treating thrombotic thrombocytopenic purpura (TTP) and autoimmune diseases are the key factors that will lead to increasing adoption of plasmapheresis as a first line of treatment.
Over the last decade or so, biologic agents have used intensively to treat cancer and autoimmune conditions. There has been rising incidence of autoimmune diseases such as type 1 diabetes, lupus, rheumatoid arthritis and psoriasis. Rampant autoimmune diseases continues to drive the demand for extracorporeal therapies. Embracement of plasmapheresis eradicates putative pathogenic autoantibodies and thereby, circulates the immune complexes from patients’ blood with systematic lupus erythematosus.
Addressing the above issue, manufacturers in the healthcare industry are relentlessly integrating innovative features and technological advancements in the plasmapheresis instruments such as aspheresis machines.
Biopharmaceutical Companies to Represent a Leading Segment
Growing need to conduct plasmapheresis has led to surge in demand for various instruments in the global market. On the basis of product type, the instruments segment is expected to represent the highest revenue growth, accounting for a value of over US$ 260 Mn by the end of 2026. However, the disposables product segment is expected to register a robust CAGR during the forecast period.
According to U.S. National Library of Medicine, the prevalence rate of TTP is in the range of 1.7 to 11 cases per million population in the U.S. In addition to TTP, increase in prevalence of autoimmune diseases and advancement in plasmapheresis is likely to drive the growth of the market during the assessment period in the U.S. The market in Europe is likely to mimic the U.S. in terms of key driving factors, whereas greater emphasis on boosting healthcare infrastructure is likely to fuel market growth in Asia Pacific excluding Japan (APEJ) and Latin America. In terms of revenues, North America will continue to be a leading market, with U.S. accounting for the bulk of revenues. The U.S. is home to some of the leading companies in the plasmapheresis market, and there is a high emphasis on research and development among universities and institutes. Collaboration between companies and institutions has also contributed to the growth of the market in the region.
Plasmapheresis Market: Overview
The report offers a coherent analysis on the plasmapheresis market for the forecast period 2018-2026. Further, the report also shed light on dynamics of the market, including drivers, trends, restraints and opportunities. Besides, the report delves into the segmentation of the market which is aimed at providing readers with an in-depth view of the market.
Browse Full Report with ToC Here:
https://www.factmr.com/report/351/plasmapheresis-market
The market for plasmapheresis adopts supply-demand approach to provide a holistic picture of the market. In-house panel of experts have thoroughly analyzed the research sources, including secondary sources and primary sources. Revenue comparison, market share comparison and Y-o-Y growth comparison on the geography lead to the market size of the plasmapheresis. The growth of manufacturers in the historical and forecast period are estimated to assist the readers with investment decisions.
Biopharmaceutical Companies to Represent a Leading Segment
Growing need to conduct plasmapheresis has led to surge in demand for various instruments in the global market. On the basis of product type, the instruments segment is expected to represent the highest revenue growth, accounting for a value of over US$ 260 Mn by the end of 2026. However, the disposables product segment is expected to register a robust CAGR during the forecast period.
Based on end users, the biopharmaceutical companies segment is expected to generate significant revenues, recording for a value of over US$ 100 Mn by the end of 2017. In contrary, the other end users segment is expected to register a significant CAGR through 2026.
Plasmapheresis Market: Competitive Landscape
Leading market players operating in the global plasmapheresis market include Haemonetics Corporation, Asahi Kasei Kuraray Medical, Terumo Corporation, B Braun Melsungen AG, Baxter Internationalaq IncR4T554RFDD., Fresenius SE & Co. KGaA, Kawasumi Laboratories, Inc. and Kaneka Corporation.
A treatment method which developed over a period of two decades and involves the removal and replacement of patient’s circulating plasma is aimed to remove disease-linked molecules and hence interrupt disease progression. Plasmapherisis has been applied in the treatment of lupus nephritis in order to eliminate circulating immune complexes and pathogenic antibodies. Accordingly, patients with overwhelming disease in whom standard therapy does not work may use plasmapheresis treatment. As such, the case of thrombotic thrombocytopenic purpura (TTP) has surged in those with SLE. Thus, priority on upgrading healthcare infrastructure coupled with growing awareness on treating TTP and autoimmune diseases has been witnessed.
Get Free Sample Report Here:
https://www.factmr.com/connectus/sample?flag=S&rep_id=351
The global plasmapheresis market is likely to grow at a steady CAGR of over 7% during the forecast period 2017-2026, and reach a valuation of over US$ 1.5 Bn by the end of 2026. The market is likely to be impacted by a range of macro-economic and micro-economic factors. Increasing emphasis on upgrading healthcare infrastructure, combined with higher awareness on treating thrombotic thrombocytopenic purpura (TTP) and autoimmune diseases are the key factors that will lead to increasing adoption of plasmapheresis as a first line of treatment.
Over the last decade or so, biologic agents have used intensively to treat cancer and autoimmune conditions. There has been rising incidence of autoimmune diseases such as type 1 diabetes, lupus, rheumatoid arthritis and psoriasis. Rampant autoimmune diseases continues to drive the demand for extracorporeal therapies. Embracement of plasmapheresis eradicates putative pathogenic autoantibodies and thereby, circulates the immune complexes from patients’ blood with systematic lupus erythematosus.
Addressing the above issue, manufacturers in the healthcare industry are relentlessly integrating innovative features and technological advancements in the plasmapheresis instruments such as aspheresis machines.
Biopharmaceutical Companies to Represent a Leading Segment
Growing need to conduct plasmapheresis has led to surge in demand for various instruments in the global market. On the basis of product type, the instruments segment is expected to represent the highest revenue growth, accounting for a value of over US$ 260 Mn by the end of 2026. However, the disposables product segment is expected to register a robust CAGR during the forecast period.
According to U.S. National Library of Medicine, the prevalence rate of TTP is in the range of 1.7 to 11 cases per million population in the U.S. In addition to TTP, increase in prevalence of autoimmune diseases and advancement in plasmapheresis is likely to drive the growth of the market during the assessment period in the U.S. The market in Europe is likely to mimic the U.S. in terms of key driving factors, whereas greater emphasis on boosting healthcare infrastructure is likely to fuel market growth in Asia Pacific excluding Japan (APEJ) and Latin America. In terms of revenues, North America will continue to be a leading market, with U.S. accounting for the bulk of revenues. The U.S. is home to some of the leading companies in the plasmapheresis market, and there is a high emphasis on research and development among universities and institutes. Collaboration between companies and institutions has also contributed to the growth of the market in the region.
Plasmapheresis Market: Overview
The report offers a coherent analysis on the plasmapheresis market for the forecast period 2018-2026. Further, the report also shed light on dynamics of the market, including drivers, trends, restraints and opportunities. Besides, the report delves into the segmentation of the market which is aimed at providing readers with an in-depth view of the market.
Browse Full Report with ToC Here:
https://www.factmr.com/report/351/plasmapheresis-market
The market for plasmapheresis adopts supply-demand approach to provide a holistic picture of the market. In-house panel of experts have thoroughly analyzed the research sources, including secondary sources and primary sources. Revenue comparison, market share comparison and Y-o-Y growth comparison on the geography lead to the market size of the plasmapheresis. The growth of manufacturers in the historical and forecast period are estimated to assist the readers with investment decisions.
Biopharmaceutical Companies to Represent a Leading Segment
Growing need to conduct plasmapheresis has led to surge in demand for various instruments in the global market. On the basis of product type, the instruments segment is expected to represent the highest revenue growth, accounting for a value of over US$ 260 Mn by the end of 2026. However, the disposables product segment is expected to register a robust CAGR during the forecast period.
Based on end users, the biopharmaceutical companies segment is expected to generate significant revenues, recording for a value of over US$ 100 Mn by the end of 2017. In contrary, the other end users segment is expected to register a significant CAGR through 2026.
Plasmapheresis Market: Competitive Landscape
Leading market players operating in the global plasmapheresis market include Haemonetics Corporation, Asahi Kasei Kuraray Medical, Terumo Corporation, B Braun Melsungen AG, Baxter Internationalaq IncR4T554RFDD., Fresenius SE & Co. KGaA, Kawasumi Laboratories, Inc. and Kaneka Corporation.
Comments
Post a Comment